

Nation Nov 24

Purdue Pharma says its guilty plea over its role in the opioid crisis is “an essential step to preserve billions of dollars” for the settlement it is pursuing in bankruptcy court.
By Geoff Mulvihill, Associated Press
Nation Oct 21

Justice Department officials tell The Associated Press that Purdue Pharma, the company that makes OxyContin, will plead guilty to three federal criminal charges as part of a settlement of more than $8 billion.
By Michael Balsamo, Geoff Mulvihill, Associated Press
Health Aug 07

States across the country are reporting an increase in opioid-related fatalities. The pandemic means adopting new methods to provide treatment for drugs and alcohol.
By Zoe Rohrich
Economy Feb 25

The English company was one of the highest-volume opioid producers in the U.S. and is seeking bankruptcy protection as part of the deal.
By Geoff Mulvihill, Associated Press
Jan 24

By Geoff Mulvihill, Associated Press
The federal judge overseeing the bankruptcy case of OxyContin maker Purdue Pharma set a June 30 deadline to file claims against the company.
Massachusetts is the only state in the country where men who are involuntarily committed for substance abuse treatment can be treated in jails.
The manufacturers and distributors of opioid prescription painkillers have supplied billions of pills throughout the U.S. An investigative series by The Washington Post looks at the opioid epidemic through the DEA's newly public database that tracks every pain pill sold…
Jul 18

Over the past two decades, hundreds of thousands of Americans have died during a national opioid addiction crisis. As the drug manufacturers face a possible legal reckoning from multiple lawsuits, a newly uncovered database sheds more light on the scope…
Jun 27

By Associated Press
The measure is modeled after a Miami-based program which also provides HIV screening, access to social services, the opioid-overdose antidote Narcan and other medical supplies.
Support Provided By: Learn more
Educate your inbox
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.